Maintenance interferon therapy in chronic hepatitis C patients who failed initial antiviral therapy

A meta-analysis

Hung-Chang Hung, MD, PhD\textsuperscript{a,b}, Hsien-Hua Liao, MD, PhD\textsuperscript{c,d}, Shiu-Chih Chen, MD, PhD\textsuperscript{c,e}, Shih-Ming Tsao, MD, PhD\textsuperscript{c,f}, Yuan-Ti Lee, MD, PhD\textsuperscript{c,f,*}

Abstract

Objectives: To evaluate the effect of pegylated interferon maintenance therapy in patients with chronic hepatitis C who failed initial antiviral therapy.

Methods: This is a meta-analysis of 6 randomized controlled trials that met the eligibility criteria. In all, 2438 chronic hepatitis C patients who failed to achieve sustained virologic response after initial treatment with pegylated interferon and ribavirin (antiviral therapy nonresponders or relapers) were enrolled; 1237 patients received maintenance therapy (Maintenance group) and 1201 received no treatment (Observation group).

Results: The pooled analyses found that patients in the Maintenance group had a significantly higher rate of normal alanine aminotransferase than did patients in the Observation group (pooled odds ratio [OR] 4.436, 95% confidence interval [CI] 1.225–16.064, \(P=0.023\)), but there was no significant difference between the 2 groups in the incidence of hepatocellular carcinoma (pooled OR 0.872, 95% CI 0.501–1.519, \(P=0.630\)), or the mortality rate (pooled OR 1.564, 95% CI 0.807–3.032, \(P=0.185\)).

Conclusions: Interferon-based maintenance therapy in patients with chronic hepatitis C who failed initial antiviral therapy improved liver inflammation as indicated by blood chemistry (alanine aminotransferase).

Abbreviations: ALT = alanine aminotransferase, CHC = chronic hepatitis C, CIs = confidence intervals, DAA = direct-acting antivirals, HALT-C = hepatitis C antiviral long-term treatment against cirrhosis, HCC = hepatocellular carcinoma, HCV = hepatitis C virus, \(I^2\) = inconsistency index, OR = odds ratio, Peg-interferon = pegylated interferon, RCTs = randomized controlled trials, SVR = sustained virologic response.

Keywords: direct-acting antivirals, HALT-C, hepatitis C virus infection, peg-interferon

1. Introduction

The number of total global hepatitis C virus (HCV) infections has been estimated to be 80 (64–103) million.\textsuperscript{[1,2]} Patients in China, Pakistan, Nigeria, Egypt, India, and Russia together have accounted for more than half of total infections.\textsuperscript{[1,2]} HCV infection causes 27% of cirrhosis and 25% of hepatocellular carcinoma cases worldwide.\textsuperscript{[3]} When cirrhosis is established, the ultimate outcome is generally poor. The mortality associated with cirrhotic chronic hepatitis C (CHC) then is usually due to end-stage liver diseases including the development of liver decompensation or hepatocellular carcinoma (HCC).\textsuperscript{[4,5]}

Before the introduction of protease inhibitors and direct-acting antivirals (DAAs) for treatment of CHC,\textsuperscript{[6,7]} the standard treatment had been interferon-\(\alpha\) and ribavirin.\textsuperscript{[8]} The efficacy of interferon regimens is measured by their ability to achieve viral clearance with cessation of disease activity, referred to as the sustained virologic response (SVR). SVR is defined as the absence of detectable HCV-RNA in serum at indicated time points after the end of treatment. CHC patients in whom initial therapy fails to achieve SVR (interferon nonresponders or relapers) become candidates for retreatment or long-term maintenance therapy. Koretz et al.\textsuperscript{[9]} stated in 2013 that some of these patients are not suitable candidates for ribavirin or protease inhibitors, but instead should be considered for retreatment with interferon alone.\textsuperscript{[4]} Long-term interferon maintenance therapy usually consists of low-dose pegylated interferon (peg-interferon) given for 1 year or more.\textsuperscript{[4,9]} With the recent availability of DAAs, the rates of SVR and virological cure have vastly increased in naive patients, and also in treatment-experienced patients.\textsuperscript{[7,10]} However,
the controversy of DAA treatment-associated risk of HCC and altered type/pattern of HCC recurrence remains. Moreover, the high economic burden of DAA had prevented its use or reimbursement by the health authorities in some parts of the world. Therefore, interferon-based regimens are still a viable approach, especially in countries where the DAAs are not available or affordable.

Our hypothesis is that continuing peg-interferon therapy long-term as maintenance therapy reduces the risk of HCC and mortality in patients with CHC who failed initial antiviral therapy.

2. Materials and methods

2.1. Search strategy

PubMed, Cochrane, and Embase were searched in July, 2017, using combinations of the following search terms: “chronic hepatitis C,” “liver cirrhosis,” “liver fibrosis,” “maintenance,” “retreatment,” “interferon,” and “antiviral.”

2.2. Selection of studies

2.2.1. Inclusion criteria. The included studies were: randomized controlled trials (RCTs) or 2-armed prospective studies of CHC; studies that enrolled patients who did not achieve a SVR after an initial treatment with interferon or interferon and ribavirin (nonresponders), or patients who relapsed after the end of the initial treatment (relapers); studies of patients who received maintenance therapy with interferon (Maintenance group) versus control without further therapy (Observation group); and studies that had quantitative outcomes.

2.2.2. Exclusion criteria. Excluded studies were: retrospective studies, reviews, letters, comments, editorials, or case reports; studies that included patients with human immunodeficiency virus coinfection; studies that included patients who had SVR after the initial treatment; studies that compared interferon of different dosages or types, or compared interferon with other antiviral agents; and studies that had no quantitative outcome.

To identify studies that were eligible for the meta-analysis, the citations were screened by a 2-step process. First, the title and abstract of each article were examined, and citations not meeting the inclusion criteria or meeting the exclusion criteria were discarded. Second, full-text copies of the remaining citations were obtained and examined to identify those who met all the inclusion criteria and none of the exclusion criteria. Two independent reviewers identified eligible studies by using the search strategy described above. If any uncertainties regarding eligibility existed, a third reviewer was consulted. The reference lists of the relevant studies were hand-searched to identify other studies that met the inclusion criteria.

2.3. Data extraction

Data as in patient demographics (number of patients, treatment regimen, age, sex, and follow-up duration) and post-treatment outcomes (rate of normal alanine aminotransferase [ALT], incidence of HCC, and incidence of death) were extracted. Two independent reviewers extracted the data from eligible studies. A third reviewer was consulted for resolution of disagreement. Patient raw data or private information were not used or extracted during this process, and thus an ethics review by the institutional review board was exempt.

2.4. Data analysis

Odds ratio (OR) with 95% confidence intervals (CIs) were calculated between patients in Maintenance group and Observation group for each included study and for all studies combined. A chi-square-based test of homogeneity was performed, and the inconsistency index ($I^2$) and Q statistics were determined. Heterogeneity was determined by use of the $I^2$ statistic, which is defined as: 0% to 24%, no heterogeneity; 25% to 49%, moderate heterogeneity; 50% to 74%, large heterogeneity; and 75% to 100%, extreme heterogeneity. As the number of studies included in the meta-analysis was small, heterogeneity tests may have low statistical power. In case of under-powered heterogeneity tests, random-effects models are routinely used.$^{10}$ The National Research Council report recommends using random-effects approaches for meta-analysis and the exploration of sources of variation in study results.$^{11}$ Pooling effects were calculated, and a 2-sided $P$ value < .05 was considered to indicate statistical significance.

Sensitivity analysis was carried out with the leave-one-out approach to investigate the validity and robustness of the results. The leave-one-out approach performs meta-analyses on each subset of the studies obtained by leaving out exactly 1 study once at a time. Publication bias, using a funnel plot, was not performed as > 10 studies are needed for this type of analysis.$^{12}$ All analyses were performed with Comprehensive Meta-Analysis statistical software, version 2.0 (Biostat, Englewood, NJ).

2.5. Quality assessment

The quality of included studies were assessed by use of the Cochrane “assessing risk of bias” table as exemplified in the Cochrane Collaboration guidelines.$^{13}$ The table has 6 assessment items, which are: random sequence generation, allocation concealment, blinding of patients and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting risk.

3. Results

3.1. Literature search

The flow chart for study selection is illustrated in Fig. 1.
Figure 1. Flow diagram of study selection.

### Table 1

Patient demographics and characteristics and maintenance protocols of the selected studies.

| First author (y) | Study design | No. of patients | Groups | Maintenance treatment protocol | Average age (y) | Male (%) | Duration of follow-up (y) |
|------------------|--------------|-----------------|--------|--------------------------------|-----------------|----------|--------------------------|
| Poynard (2013)   | RCT          | 270             | Maintenance | Peg-IFNα-2b, 0.5 μg/kg/wk, for 2.3 y | 49.8           | 72%      | 3.6                      |
|                  |              | 270             | Observation |                                   | 49.2           | 70%      | 3.9                      |
| Bruix (2011)     | RCT          | 311             | Maintenance | Peg-IFNα-2b, 0.5 μg/kg/wk, for a maximum period of 5 y | 52.3           | 66%      | 5                        |
|                  |              | 315             | Observation |                                   | 52             | 68%      |                          |
| DiBisceglie (2008)| RCT         | 517             | Maintenance | Peg-IFNα-2a, 90 μg/wk for 3.5 y | 51.1           | 70%      | 3.5                      |
|                  |              | 533             | Observation |                                   | 50.1           | 73%      |                          |
| Alric (2001)     | RCT          | 29              | Maintenance | Gradual tapering of IFN dose during 12 mos: 2 M IU 3 times weekly for 3 mos, 1 M IU 3 times weekly for 3 mos, 1 M IU twice a wk for 3 mos, and 1 M IU once a wk for the last 3 mos | 46.3           | 45%      | 2.5                      |
|                  |              | 28              | Observation |                                   | 45.8           | 43%      |                          |
| Shiffman (2009)  | RCT          | 26              | Maintenance | IFNα-2b, 3 M IU 3 times weekly for 24 mos | 47.8           | 58%      | 2                        |
|                  |              | 27              | Observation |                                   | 48.8           | 52%      |                          |
| Bresci (1995)    | RCT          | 28              | Maintenance | Recombinant IFNα, 3 M IU thrice weekly for 6 mos | 47             | 64%      | 0.5                      |
|                  |              | 28              | Observation | Recombinant IFNα, 6 M IU thrice weekly for 6 mos | 48             | 57%      |                          |
|                  |              | 28              | Observation | lymphoblastoid-IFN, 3 M IU thrice weekly for 6 mos | 45             | 61%      |                          |

IFN = interferon, IU = international unit, M = million, peg-IFN = pegylated interferon, RCT = randomized controlled trial.
analysis found that patients in Maintenance group had significantly higher rate of normal ALT than did patients in Observation group (pooled OR 4.436, 95% CI 1.225–16.064, \( P = .023 \)) (Fig. 2A).

Only 2 of the RCTs in the meta-analysis\(^{[14,18]}\) provided the incidence rates of HCC. No heterogeneity was observed in the 2 studies (Q-statistic = 0.051, \( I^2 = 0\% \)). The pooled analysis found that there was no significant difference in the incidence of HCC between patients in Maintenance group and Observation group (pooled OR 1.564, 95% CI 0.807–3.032, \( P = .185 \)) (Fig. 2B).

Three of the RCTs provided data on mortality.\(^{[14,18,19]}\) There was no heterogeneity among these studies (Q-statistic = 0.597, \( I^2 = 0\% \)). The pooled analysis found no significant difference in the mortality rate among patients in Maintenance group and Observation group (pooled OR 1.564, 95% CI 0.807–3.032, \( P = .185 \)) (Fig. 2C).

### 3.4. Sensitivity analysis

Sensitivity analyses were performed by the leave-one-out approach, in which the meta-analysis was performed with each study removed in turn (Table 2). The direction and magnitude of combined estimates of neither HCC incidence nor mortality varied significantly upon removal of the studies, indicating that
the meta-analysis had good validity and robustness, and the data were not overly influenced by each study. Pooled OR of normal ALT at follow-up remained >1 after each study was removed in turn, despite after the removals of 2 individual studies,[16,17] the OR became borderline significant, indicating no obvious influence of any individual study on the pooled estimate.

3.5. Quality assessment

Quality assessment of the studies is illustrated in Fig. 3. The quality of included studies was moderate. The most significant risk of bias came from performance bias (blinding of participants and personnel) because Observation group received no placebo drugs as described in studies by Bruix et al[18] and Poynard et al[19]; meanwhile, the other 4 studies did not give information about the concealment of treatment.

4. Discussion

The key findings of this meta-analysis were that interferon maintenance therapy improved the rate of normal serum ALT compared with the control group,[14–17] but there was no difference in mortality or incidence of HCC between the 2 groups. These results are consistent with those reported by Koretz et al,[4] published in Cochrane Database Systematic Review. Koretz et al included RCTs comparing interferon versus placebo or no treatment in CHC nonresponders and relapers to previous interferon treatment with severe hepatic fibrosis. Based on all 7 trials, no significant difference was found in all-cause mortality, hepatic mortality, or incidence of HCC. In 2 combined trials in the meta-analysis with low risk of bias, the all-cause mortality was significantly higher in the interferon-treated patients. Similar findings have been reported by Di Bisceglie et al,[20] who concluded that long-term maintenance peg-interferon in patients with advanced CHC is associated with an excess overall mortality, primarily due to nonliver-related causes among patients with bridging fibrosis. In the Koretz et al study,[4] serum ALT values, which can reflect hepatic damage, were not analyzed, but histologic evidence of inflammation was improved by interferon treatment.

Only 2 studies[14,18] in the present meta-analysis reported HCC incidence, and found that maintenance therapy with interferon did not prove to be beneficial. This is in line with that reported by Lok et al,[21] who extended the duration of follow-up of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial and found that long-term low-dose peg-interferon therapy did not reduce the incidence of HCC among patients with advanced hepatitis C who did not achieve SVRs. Thus, the hope to adopt maintenance interferon therapy to reduce the chances of HCC developing in CHC patients who failed initial treatment has not been fulfilled.

An inevitable impression of using interferon as a therapy for CHC is the drug’s frequent and troubling side effects, including fatigue, headache, chills/rigors, fever, musculoskeletal pain, and weight loss. In the systematic review by Koretz et al,[4] the authors noted an increase in adverse effects and a significantly worse pain score in interferon-treated patients compared with placebo-treated patients or untreated patients. Partly because of these side effects, interferon-based regimens are poorly tolerated. Steffen et al[22] have stated that patients with higher motivation and compliance should be considered for maintenance interferon therapy of CHC.

Dose adjustment of interferon may ameliorate the side effects associated with the drug, and indeed an extended low-dose interferon trial performed by Tarantino et al[23] has shown to increase SVR rates in patients with prior complete response at the end of standard treatment. However, the HALT-C trial found that low-dose peg-interferon therapy was still associated with worsening of health-related quality of life, symptoms, and male patients’ sexual health, despite that cognitive function and depression were less affected.[14–26] Furthermore, lower doses of interferon were used in several studies included for analysis in this report,[14,15,18,19] but the efficacy findings were not altered in the sensitivity test where individual studies were taken out. This implies that dose of interferon plays a minor role in the efficacy of interferon-based maintenance therapy in nonresponders/relapers.

We acknowledge that this meta-analysis has limitations. First, only 6 RCTs were included. Second, the number of patients is small in 3 of the included studies (54–56 patients each).[15–17] Third, scoring systems for evaluating fibrosis, definition of nonresponder, and therapy before maintenance treatment varied among studies. Fourth, a partial overlap of patient populations among 2 studies may have occurred: Poynard et al[19] included adult patients with CHC infection and biopsy-confirmed moderate to severe fibrosis from EPIC,[3] and Bruix et al[18] included all patients who had compensated biopsy-proven cirrhosis (Child-Pugh class A) from EPIC.[3]
Shiffman\textsuperscript{27} wrote in 2010 that “Based upon the available data, there appears to be no rationale for utilizing PEG-IFN maintenance therapy in patients with cirrhosis, and this approach does not reduce the risk of HCC.” Regrettably, research in the ensuing years has yielded little grounds for reversal of this opinion. Major outcome variables in patients treated with long-term interferon products have not been improved, although modest positive responses have been observed in ALT improvements,\textsuperscript{14–17} attaining SVR at a significant but low (22\%) rate,\textsuperscript{28} reducing progression of fibrosis,\textsuperscript{19} and improving disease activity scores.\textsuperscript{19}

In the DAA era that we currently stand,\textsuperscript{7} better options than interferon-based regimens are available for treating CHC. Interferon-based maintenance for CHC may still be considered in clinical settings where DAAAs are unavailable or unaffordable, but as Heim\textsuperscript{29} wrote in 2013, the interferon epoch is coming to an end.
5. Conclusions
This meta-analysis found that interferon-based maintenance therapy of CHC may improve ALT, a biochemical indicator of liver inflammation. However, similar to previous studies, this maintenance therapy did not reduce the incidence of HCC or mortality. Further study of this therapy seems unlikely to yield a significantly different view or clinically meaningful results.

Author contributions
Conceptualization: Yuan-Ti Lee.
Data curation: Hung-Chang Hung, Shih-Ming Tsao.
Formal analysis: Hsien-Hua Liao, Shiuan-Chih Chen, Shih-Ming Tsao.
Investigation: Hung-Chang Hung.
Writing – original draft: Hung-Chang Hung, Hsien-Hua Liao, Shiuan-Chih Chen, Shih-Ming Tsao, Yuan-Ti Lee.
Writing – review & editing: Yuan-Ti Lee.

References
[1] Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61:543–57.
[2] Lim SG, Agbemo A, Chen PJ, et al. Management of hepatitis C virus infection in the Asia-Pacific region: an update. Lancet Gastroenterol Hepatol 2017;2:52–62.
[3] Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529–538.
[4] Koretz RL, Peguesuelo M, Arvani V, et al. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database Syst Rev 2013;1:CD006167.
[5] Khullar V, Firpi RJ. Hepatitis C: cirrhosis: new perspectives for diagnosis and treatment. World J Hepatol 2013;5:1843–55.
[6] Jakobsen JC, Nielsen EE, Femborg J, et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev 2017;9:CD012143.
[7] Omata M, Kanda T, Wei L, et al. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int 2016;10:681–701.
[8] Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975–82.
[9] Shiffman ML. Impact of peginterferon maintenance therapy on the risk of developing hepatocellular carcinoma in patients with chronic hepatitis C virus. Oncology 2010;78(suppl 1):11–6.
[10] Takkouche B, Cadarso-Suárez C, Spiegelman D. Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. Am J Epidemiol 1999;150:206–15.
[11] National Research Council. Combing Information: Statistical Issues and Opportunities for Research. Washington, DC: National Academy Press; 1992.
[12] Sterne JA, Sutton A J, Ioannidis F P, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002.
[13] Higgins J, Green S. Cochrane handbook for systematic reviews of interventions Version 5.1. 0 [updated March 2011]. Chichester, West Sussex, UK: The Cochrane Collaboration; 2011.
[14] Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008;359:2429–41.
[15] Alric L, Dufaut M, Selves J, et al. Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial. J Hepatol 2001;35:272–8.
[16] Shiffman ML, Morishima C, Dienstag JL, et al. Effect of HCV RNA suppression during peginterferon Alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology 2009;137:1986–94.
[17] Bresci G, Parisi G, Banni S, et al. Re-treatment of interferon-resistant patients with chronic hepatitis C with interferon-alpha. J Viral Hepatitis 1995;2:155–88.
[18] Bruix J, Pynard T, Colombo M, et al. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology 2011;140:1990–9.
[19] Pynard T, Bruix J, Schiff ER, et al. Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study. J Hepatol 2013;58:452–9.
[20] Di Bisceglie AM, Stodard AM, Dienstag JL, et al. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology 2011;53:1109–8.
[21] Lok AS, Everhart JE, Wright EC, et al. Maintenance peginterferon therapy and other factors associated with hepaticcellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011;140:840–9.
[22] Steffen M, Cornberg M, Buggisch P. Treatment of chronic hepatitis C with consensus interferon in relapsers and non-responders to interferon-based therapy. Hepatogastroenterology 2007;54:2368–72.
[23] Tarantino G, Sorrentino P, Conca P, et al. Low daily dosage of interferon for 1 year after HCV-related end-therapy response. A randomized-controlled study. Liver Int 2003;23:413–9.
[24] Snow KK, Bonkovsky HL, Fontana RJ, et al. Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C. Aliment Pharmacol Ther 2010;31:719–34.
[25] Fontana RJ, Bialaskas LA, Back-Madruja C, et al. Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C. Am J Gastroenterol 2010;105:1551–60.
[26] Kronfli Z, Litman HJ, Back-Madruja C, et al. No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C. J Affect Disord 2011;129:205–12.
[27] Shiffman ML. Impact of peginterferon maintenance therapy on the risk of developing hepatocellular carcinoma in patients with chronic hepatitis C virus. Oncology 2010;78(suppl 1):11–6.
[28] Pynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009;136:1618–28.
[29] Heim MH. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol 2013;13:335–42.